Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

ASSESS Study - 24 Months

  Channels: | Posted 5/17/2016

Rishi P. Singh, MD, reviews details of the ASSESS study, which transitioned patients who had previously been treated with bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) to aflibercept (Eylea, Regeneron). The results of this study and its 24-month extension may help guide clinicians treating patients who have received previous treatments with other anti-VEGF drugs.

AMD • AMD Disease Education Resource Center • Clinical Trials • Regeneron Pharmaceuticals • Wet AMD